Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 3)

• Status: Completed
• Trial end date: 2019-08-07
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of study is to confirm the efficacy of DWP14012 Xmg, Once daily, compared to esomeprazole 40mg in patients with erosive gastroesophageal reflux disease.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Daewoong Pharmaceutical Co. LTD.
• Treatments: Esomeprazole

Criteria

Inclusion Criteria:

• Adults between 20 and 75 years old based on the date of written agreement

• Those who have been diagnosed with erosive gastroesophageal reflux disease(EGRD) of LA Grade A-D on the upper gastrointestinal endoscopy

• Those who experienced symptoms of heartburn or acid regurgitation within the last 7 days

Exclusion Criteria:

• Those who have undergone gastric acid suppression or gastric, esophageal surgery

• Those who with clinically significant liver, kidney, nervous system, respiratory, endocrine, hematologic, cardiovascular, urinary system disease